Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 123.11B P/E 15.65 EPS this Y 11.90% Ern Qtrly Grth -
Income 3.76B Forward P/E 13.67 EPS next Y 5.20% 50D Avg Chg 2.00%
Sales 29.53B PEG 2.86 EPS past 5Y 4.22% 200D Avg Chg -7.00%
Dividend 3.00% Price/Book 23.02 EPS next 5Y 5.97% 52W High Chg -22.00%
Recommedations 2.40 Quick Ratio 0.84 Shares Outstanding 536.44M 52W Low Chg 9.00%
Insider Own 0.25% ROA 4.88% Shares Float 534.94M Beta 0.58
Inst Own 80.91% ROE 72.58% Shares Shorted/Prior 8.98M/9.05M Price 230.41
Gross Margin 66.49% Profit Margin 12.74% Avg. Volume 2,558,209 Target Price 320.24
Oper. Margin 13.33% Earnings Date Aug 1 Volume 2,550,177 Change -0.74%
About Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen Inc. News
07/24/24 What Lies in Store for Healthcare ETFs in Q2 Earnings?
07/23/24 Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
07/23/24 Investors in Amgen (NASDAQ:AMGN) have seen splendid returns of 122% over the past five years
07/23/24 Nanotechnology in medicine: Who are the leading public companies?
07/22/24 Dow Jones Leader Amgen, Nvidia Stock, Coinbase In Or Near Buy Zones
07/22/24 Beat the Market Like Zacks: Karooooo, UnitedHealth, Amgen in Focus
07/22/24 Pipeline Moves: Novo Nordisk progression prospects drop after candidate terminated
07/19/24 Amgen (AMGN) Ascends While Market Falls: Some Facts to Note
07/19/24 Rivals Emerge to Ozempic and Zepbound—but With a Lag
07/19/24 The Zacks Analyst Blog NVIDIA, Meta and Amgen Galaxy Gaming
07/18/24 Amgen (AMGN) Dips More Than Broader Market: What You Should Know
07/18/24 Q2 Earnings Season Scorecard, Economic Outlook and Analyst Reports for NVIDIA, Meta & Others
07/18/24 Insiders At Amgen Sold US$6.5m In Stock, Alluding To Potential Weakness
07/16/24 Why Investors Need to Take Advantage of These 2 Medical Stocks Now
07/15/24 3 Biotech Stocks to Buy Now: Q3 Edition
07/15/24 Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
07/15/24 What Is the Dividend Payout for Amgen Stock?
07/14/24 3 Dividend Growth Stocks to Buy and Hold
07/13/24 Amgen Inc.'s (NASDAQ:AMGN) high institutional ownership speaks for itself as stock continues to impress, up 6.4% over last week
07/12/24 Amgen (AMGN) Rises Higher Than Market: Key Facts
AMGN Chatroom

User Image Babe1984 Posted - 11 hours ago

$VKTX Now $vktx molecule will be on par with $amgn with better efficacy and tolerability! FDA must have really liked what they have seen to give $vktx green light for p3!

User Image DefenseMania Posted - 11 hours ago

$ABBV $GILD $AMGN $LMT like the tortoise and the hair compared to all the AI stocks crashing Friday will be the big sell off day

User Image dcpanda Posted - 14 hours ago

$ICU $AMGN just buy it!

User Image howardlindzon Posted - 14 hours ago

$UNH all-time highs, $amgn all time highs, $isrg all time highs... when tech stumbles...lots of other big name working...

User Image PurpleTie Posted - 14 hours ago

$AMGN so much strength with this stock. I should have bought at $324 when the opportunity presented, now I’m chasing before earnings .

User Image AlphaInstinct Posted - 1 day ago

$HIMS excited to see Kåre Schultz on board - successful leaders joining such a young company is always a good sign. We’re going to $30 either way. $NVO $AMGN $LLY

User Image PurpleTie Posted - 1 day ago

$AMGN a little pullback for this stock is healthy after the big run in the last week. I just need my buy order at $330 to fill then this can rip to $350 after earnings. 🚀

User Image Motherloads Posted - 1 day ago

$AMGN ✈️⭐️🔥✅

User Image KStocks12 Posted - 2 days ago

$AMGN Second time today it touches $350? both pre market and now after hours!

User Image Invest2pro Posted - 2 days ago

$ESPR Nexlizet changed my wife's life & is an AMAZING drug. $AMGN would be smart to buy Esperion before the scripts take off & more people stop taking Repatha like my wife did

User Image JFDI Posted - 2 days ago

$AMGN on da run.

User Image Shmack23 Posted - 2 days ago

$AMGN $ESPR $CVNA This is pretty much the buy side case...yes. "My wife prefers a pill to the shot." Easy enough. Congrats to your wife for switching to a better alternative! Best wishes to her health.

User Image Invest2pro Posted - 2 days ago

$CVNA This has had a great run. I bought in at $40. I sold out today to buy into another investment $ESPR which has tremendous growth ahead. ESPR has two drugs that will be blockbusters. My wife takes 1 which is NEXLIZET, it is a non statin drug oral pill & recently the FDA changed it to the only non statin alternative with a primary prevention label. It is off the radar & the company is setting itself up for sale. buy a little if you have extra cash. Company will be profitable within 6 months, but $AMGN will have bought them by then. My wife stopped taking Repatha which is AMGN pcsk9 injection and started on Nexlizet, that is why I am investing in ESPR.

User Image Invest2pro Posted - 3 days ago

$ESPR Dr C.Michael Gibson has around 437k followers, & Dr Gibson follows Heartsage which makes Heartsage info credible with his direct conversation that is very meaningful with Brinks & Brinks shared it on twitter tagging Dr Gibson, so it's not BS. Dr Gibson didn't read it the tweet accurately & thought Brinks was saying Dr Gibson said the remarks about AMGN & Repatha. I can also relate because my wife was taking Repatha $AMGN drug & has since switched to NEXLIZET which is working very well for her. I also just finished a bottle of red.

User Image DrBenGalper Posted - 3 days ago

$ESPR I anticipate about 25% of my patient population to be taking Nexlizet or Nexletol in combination with or without a statin. It is clear for me Esperion therapeutics drug Bemepedoic acid will be a blockbuster drug & generate billions in annual sales. Bemepdoic acid & Ezetimibe are a perfect synergism. Lipitor/ atorvastatin (Generic) is the world leading drug in sales. More & more of my patients are concerned about statin drugs regardless of intolerance. Nexlizet is the perfect answer. I would highly bet Esperion is acquired by big name. I read some think $AMGN & that makes good sense to me, I am expecting Repatha & other PCSK9 injections being moved as a statin alternative option until a patient has tried Nexlizet, which in my opinion will be the leading statin alternative across the globe.

User Image Invest2pro Posted - 4 days ago

$ESPR WOW. Fantastic #'s. Thank you Gary. I actually think ASPN is filling more scripts than the weekly % growth. Earnings will be really good. Brinks is confident $AMGN is going to pay up for Esperion.

User Image sanjoy123 Posted - 4 days ago

$AMGN Still bullish signal. Amgen (AMGN) stock has experienced an upward trend over the past month due to several positive developments. The company's recent earnings report for Q1 2024 exceeded expectations, with earnings per share (EPS) of $3.96 compared to the analyst estimate of $3.87, and revenue of $7.45 billion, which was significantly higher than the projected $6.94 billion​ Additionally, Amgen is anticipated to benefit from multiple upcoming catalysts in 2024, including advancements in its pipeline for treatments targeting significant markets such as obesity and chronic obstructive pulmonary disease (COPD). The release of promising data from trials of their obesity drug AMG 133 and other therapeutics in their pipeline has fueled investor optimism​. Furthermore, analyst upgrades and increased target prices have contributed to the positive sentiment surrounding Amgen, supporting the stock's recent rise​

User Image GemsBot Posted - 4 days ago

1 of 11 $AAPL $AMGN $AMZN Daily and 30 min charts of the DJIA Components with the SSI indicator, a proprietary indicator based exclusively on the eSignal platform, are posted here weekends … see 2/11

User Image KenFaulkenberry Posted - 5 days ago

1What is the Intrinsic Value of Amgen (AMGN)? $AMGN Stock Analysis: https://dividendvaluebuilder.com/amgen-amgn-dividend-stock-analysis/

User Image DefenseMania Posted - 5 days ago

$LLY thinking some news of brewing next week for RCUS $ABBV $AMGN $MRNA $NVS

User Image TalkMarkets Posted - 6 days ago

Q2 Earnings Season Scorecard, Economic Outlook And Analyst Reports For Nvidia, Meta & Others $AMGN $NVDA $GLXZ $META https://talkmarkets.com/content/stocks--equities/q2-earnings-season-scorecard-economic-outlook-and-analyst-reports-for-nvidia-meta--others?post=454849

User Image Quantumup Posted - 1 week ago

Jefferies🏁 $TNGX Buy/$19~lead assets '908/'462 r selective PRMT5-MTA inh 4 MTAP-del cancers, which r ~10-15% of all tumors. '908 is focused on GBM '462 may have better eff vs comps (based on preclin potency & selectivity)4other tumor types. 2H24 Data4both=major derisking: $idya $amgn

User Image ziggma_official Posted - 1 week ago

$AMGN Hitting new highs. So is valuation. Graham long-term PE is hitting 30x, Price to Sales in excess of 6x. https://app.ziggma.com/securities/AMGN#analysis

User Image Stocksrunner Posted - 1 week ago

Big money's betting on biotech: 17 of 27 recent 13F filers are holding Amgen. This Wall Street vote of confidence could fuel the already-hot $AMGN stock. With institutional backing and solid performance, Amgen might just be primed for liftoff. Keep watch as this biotech powerhouse gains momentum. https://stocksrunner.com/symbol/amgn

User Image QuantTheta Posted - 1 week ago

$AMGN Bullish break resumption

User Image DZee Posted - 1 week ago

$AMGN likely to see a short term dip. Will continue to make new highs.

User Image themarker Posted - 1 week ago

Cathie Wood and Ark Invest's trade activity from 2024/07/15 $AMGN $BLDE $GH $NTRA $OKLO

User Image Quantumup Posted - 1 week ago

Stifel⬆️ $RVMD $57 was $43/Buy +⬆️RMC-6236's PoS for G12D and G12V PDAC to 75%: Wedbush⬆️ $RVMD $59 was $46/Outperform: Piper Sandler⬆️ $RVMD to $57 was $43/Overweight, says it's a matter of when, not if RMC-6236 becomes the SoC to Tx 2nd-line PDAC: Leerink⬆️ $RVMD $53 was $48/Outperform: $amgn $bmy $mrk

User Image SparkyReturns Posted - 1 week ago

$XERS Can you imagine what will happen if they monetize subQ Levo (XP-8121) with a partnership? Or if they announce $regn is exercising a license for some MAbs with a nice up-front payment? Or if they disclose the terms of their other unknown up-front payments and milestones from $amgn and Beta Bionics? We are just getting started. I'm surprised we haven't heard of any deals with $BMY or $LLY yet. Cheers!

User Image Stoxpo Posted - 1 week ago

From Oppenheimer on GLP-1 & $VKTX 📢👇👇 Future Directions in Obesity Treatment: Survey Insights and Innovations 'We believe our survey results support the opportunities for AMGN's MariTide (AMG 133) and VKTX's VK2735 based on their potential to address gaps in the treatment landscape' https://stoxpo.com/index.php/2024/07/15/future-directions-in-obesity-treatment-survey-insights-and-innovations/ $VKTX $AMGN $QQQ

Analyst Ratings
Morgan Stanley Equal-Weight Jul 11, 24
Argus Research Buy Jun 27, 24
RBC Capital Outperform Jun 14, 24
Mizuho Neutral May 9, 24
RBC Capital Outperform May 3, 24
Morgan Stanley Equal-Weight May 3, 24
UBS Neutral May 3, 24
William Blair Outperform May 3, 24
BMO Capital Outperform May 3, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Grygiel Nancy A. SVP & CCO SVP & CCO Dec 04 Sell 273.0323 2,096 572,276 10,874 12/04/23
Graham Jonathan P EVP, Gen. Counsel &.. EVP, Gen. Counsel & Secy. Nov 08 Sell 272.8136 10,000 2,728,136 28,078 11/13/23
Gordon Murdo EVP, Global Commerci.. EVP, Global Commercial Ops Aug 10 Sell 262.43 9,558 2,508,306 44,308 08/11/23
Khosla Rachna SVP, Business Develo.. SVP, Business Development Nov 09 Sell 292.90 387 113,352 6,630 11/10/22
Grygiel Nancy A. SVP & CCO SVP & CCO Nov 05 Sell 293.54 545 159,979 13,009 11/08/22
Williams R Sanders Director Director Aug 22 Sell 249.96 200 49,992 5,301 08/22/22
ECKERT ROBERT Director Director Aug 18 Sell 248.9966 6,600 1,643,378 21,184 08/19/22
ECKERT ROBERT Director Director Aug 10 Option 85.59 20,000 1,711,800 34,575 08/12/22
Williams R Sanders Director Director May 23 Sell 250.00 600 150,000 5,501 05/23/22
Graham Jonathan P EVP, Gen. Counsel &.. EVP, Gen. Counsel & Secy. May 10 Sell 241.8114 13,500 3,264,454 37,333 05/10/22
SUGAR RONALD D Director Director May 12 Option 71.64 1,000 71,640 16,927 05/12/21
SUGAR RONALD D Director Director May 12 Sell 250.59 1,000 250,590 15,927 05/12/21
Grygiel Nancy A. SVP & CCO SVP & CCO May 12 Option 162.6 2,500 406,500 14,961 05/12/21
Grygiel Nancy A. SVP & CCO SVP & CCO May 12 Sell 252.51 2,500 631,275 12,461 05/12/21
SUGAR RONALD D Director Director Apr 15 Option 71.64 1,000 71,640 16,927 04/15/21
SUGAR RONALD D Director Director Apr 15 Sell 249.98 1,000 249,980 15,927 04/15/21
SUGAR RONALD D Director Director Mar 10 Option 71.64 1,000 71,640 16,805 03/10/21
SUGAR RONALD D Director Director Mar 10 Sell 231.53 1,000 231,530 15,805 03/10/21
Bradway Robert A Chairman, CEO and Pr.. Chairman, CEO and President Feb 22 Option 54.69 73,500 4,019,715 618,380 02/22/21
REESE DAVID M EVP, Research and De.. EVP, Research and Development Feb 16 Option 54.69 2,300 125,787 42,059 02/16/21
SUGAR RONALD D Director Director Feb 10 Option 71.64 1,000 71,640 16,805 02/10/21
SUGAR RONALD D Director Director Feb 10 Sell 238.4 1,000 238,400 15,805 02/10/21
SUGAR RONALD D Director Director Jan 14 Option 71.64 1,000 71,640 16,805 01/14/21
SUGAR RONALD D Director Director Jan 14 Sell 235.99 1,000 235,990 15,805 01/14/21